The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | How does CAR-T therapy compare to stem cell transplantation?
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into the role of CAR-T therapy versus stem cell transplantation (SCT) in multiple myeloma and whether transplant will be replaced in the next five years. Dr Lin emphasizes the importance of the upcoming CARTITUDE-6 trial (NCT05257083), which will be comparing induction therapy followed by SCT and lenalidomide maintenance versus induction therapy followed by ciltacabtagene autoleucel (cilta-cel) and lenalidomide maintenance in patients with high-risk multiple myeloma, and will answer some very important questions in the field. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
